Brorphine is primarily used in scientific studies involving opioid receptor pharmacology. Due to its strong affinity for the μ-opioid receptor, it serves as a powerful reference compound for understanding synthetic opioid behavior. Researchers examine its pharmacodynamic and pharmacokinetic properties to study analogs of potent opioids, toxicity pathways, receptor selectivity, and binding affinity.

• μ-Opioid Receptor Binding Studies
  Brorphine’s primary mechanism of action is μ-opioid receptor agonism, making it valuable in studies that examine how synthetic opioids interact with neural pathways associated with pain and reward.

• Comparative Potency Testing
  Researchers use Brorphine as a benchmark for comparing the potency of other novel opioids. It helps establish efficacy and safety profiles in in-vitro and in-vivo models.

• Structure-Activity Relationship (SAR) Modeling
  Brorphine’s structure offers a unique template in SAR research. Its benzimidazole core and piperidine substitution allow for modifications that help determine how molecular changes influence activity.

• Toxicology and Overdose Mechanism Research
  Its involvement in recent public health events makes Brorphine relevant for overdose modeling. Toxicologists use it to study respiratory depression, CNS suppression, and the role of synthetic opioids in mortality.

• Forensic Chemistry Calibration
  Brorphine is used in forensic laboratories to create calibration standards for detection methods like LC-MS/MS, which help in identifying its presence in toxicological screens.

• Receptor Selectivity Profiling
  Brorphine is evaluated for its selectivity toward μ-opioid receptors over δ or κ receptors, helping researchers understand its abuse potential and side effect profile.

• Synthetic Analog Development
  Scientists use Brorphine’s core as a base for synthesizing and evaluating structurally similar analogs to probe therapeutic potential or toxicity.

Brorphine’s legal status varies significantly across jurisdictions. While it is controlled in several countries, it remains unscheduled in others, often falling into grey legal areas. Researchers are strongly advised to verify local laws before ordering or possessing Brorphine.

• United States
  Brorphine is classified as a Schedule I substance under the Controlled Substances Act, meaning it is considered to have no accepted medical use and high abuse potential.

• European Union
  Several EU member states have placed Brorphine under emergency control measures or analog laws. Countries like Sweden, Germany, and the UK list it under temporary bans or psychoactive substance legislation.

• Canada and Australia
  While not individually listed in all provinces or states, Brorphine can fall under analog provisions due to structural similarity to other opioids.

• Asia and Africa
  Legal status is inconsistent. Some countries may not list Brorphine at all, allowing importation for research purposes, while others may regulate it under catch-all chemical control laws.

• Import Responsibility
  RC Plug does not ship Brorphine to locations where it is controlled. It is the buyer’s responsibility to ensure compliance with local chemical importation laws.

• Analog Laws
  In some regions, Brorphine may be considered illegal under analog statutes even if not explicitly named, particularly if intended for human consumption.

• Research Exemptions
  In certain countries, Brorphine may be allowed for scientific research under controlled conditions with proper institutional approval.

Brorphine’s structure is a benzimidazole-based synthetic opioid that mimics the functional properties of more commonly known compounds like fentanyl, but with a different molecular backbone. Its unique configuration is central to its potency and pharmacological behavior.

• IUPAC Name
  Its systematic name is 1-[1-[1-(4-bromophenyl)ethyl]-piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one, reflecting its benzimidazole core and piperidine functional group.

• Molecular Formula
  The compound’s formula is C22H26BrN3O, indicating the presence of a brominated aromatic ring, nitrogenous groups, and a benzimidazole framework.

• Molecular Weight
  Brorphine has a molecular weight of 428.37 g/mol, making it relatively large and lipophilic, which contributes to its ability to cross biological membranes.

• Key Structural Components
  It contains a 4-bromophenyl group, which is believed to enhance receptor binding, and a piperidine ring, which is commonly seen in potent opioids.

• Structural Class
  Brorphine belongs to the benzimidazole opioid class, distinguishing it from fentanyl (an anilide) and U-series opioids (which are diarylamines).

• Structural Variability for Analogs
  Its scaffold allows for substitutions that can drastically alter receptor affinity, enabling the development of analogs for broader pharmacological study.

• 3D Configuration
  The presence of chiral centers and rigid cyclic components suggests that stereochemistry plays a significant role in its receptor interaction profile.

Brorphine is a highly potent synthetic opioid, considered several times stronger than morphine in preclinical research models. Although exact human comparisons are not feasible due to ethical constraints, its in-vitro and animal model data indicate extreme potency.

• Estimated Potency
  Research estimates place Brorphine’s potency at 10 to 20 times that of morphine, depending on the assay and biological model used.

• μ-Opioid Receptor Affinity
  Brorphine displays strong binding affinity for μ-opioid receptors, a key factor behind its pronounced pharmacological effects.

• In-Vivo Studies
  Rodent models suggest Brorphine induces analgesic and sedative effects at lower doses than morphine or oxycodone.

• Comparisons to Fentanyl
  While not as potent as fentanyl (50–100x morphine), Brorphine has comparable receptor activity and CNS depressant potential.

• Duration of Action
  Brorphine has a moderate duration (3–6 hours), which is longer than some rapid-onset opioids, potentially increasing its cumulative effect.

• Risk of Respiratory Depression
  Like other potent opioids, Brorphine carries a significant risk of respiratory depression in misuse models, warranting extreme caution in handling.

• Low Dose Thresholds
  Due to high potency, even microgram-level amounts can produce noticeable pharmacological effects, emphasizing the importance of precision dosing in research.

No. Brorphine is strictly prohibited from any form of human or veterinary application. It is not approved by any regulatory health authority for therapeutic use and must be restricted to controlled laboratory environments.

• Not Clinically Approved
  Brorphine has never undergone clinical trials or received approval from regulatory agencies such as the FDA, EMA, or WHO for any therapeutic indication.

• Toxicity and Safety Unknowns
  Comprehensive data on its safety profile, toxicity thresholds, and side effect spectrum in humans or animals is unavailable, making its use outside a lab setting highly dangerous.

• Ethical Restrictions
  The use of Brorphine in clinical or veterinary experiments would require extensive institutional ethics review and legal permissions, which are rarely granted.

• Research Use Only Labeling
  At RC Plug, all Brorphine products are clearly labeled “For Research Use Only” and are intended solely for analytical, forensic, or laboratory-based applications.

• No Dosing Guidelines for Humans
  There are no validated dosing or administration guidelines for humans, making any non-research use highly unpredictable and potentially fatal.

• Legal Ramifications
  Using or distributing Brorphine for human consumption may result in severe legal consequences under drug trafficking or endangerment laws.

• Safety Risk to Animals
  Even in veterinary contexts, the use of unapproved synthetic opioids like Brorphine poses unacceptable risks, including fatal overdose.

Brorphine is a potent research chemical that poses serious health risks if mishandled. Due to its opioid activity and high potency, laboratory staff must exercise extreme caution during storage, measurement, and experimentation. Even minor exposure—especially via inhalation or skin contact—can result in severe physiological effects.

• Use of Personal Protective Equipment (PPE)
  Always wear nitrile gloves, lab coats, and chemical splash goggles when handling Brorphine. Due to its high potency, skin contact must be avoided at all costs.

• Ventilation and Fume Hoods
  Work within a certified fume hood or well-ventilated biosafety cabinet to avoid inhalation of any airborne particles or dust generated during weighing or transfer.

• Dust and Aerosol Management
  Brorphine’s fine powder form can easily become airborne. Always use low-static tools and handle it on antistatic weighing paper or in closed systems.

• Emergency Exposure Protocols
  Labs should maintain naloxone (an opioid antagonist) on-site in case of accidental exposure. Immediate medical attention must follow any suspected ingestion, inhalation, or dermal exposure.

• Prohibited Lab Practices
  Never pipette by mouth, handle Brorphine near food or drink, or use common utensils when measuring. Cross-contamination risks are high and must be mitigated.

• Labeling and Documentation
  Clearly label all vials, containers, and storage units with hazard information. Use chemical inventory logs to track usage and prevent misplacement.

• Training Requirements
  Only qualified personnel trained in handling hazardous research chemicals should work with Brorphine. Annual lab safety certifications are recommended.

To preserve its chemical integrity and reduce safety risks, Brorphine must be stored in a stable, controlled environment. Proper storage not only extends the compound’s shelf life but also ensures consistent results in analytical procedures.

• Refrigerated Conditions
  Store Brorphine at temperatures between 2°C and 8°C, ideally in a dedicated chemical refrigerator. Avoid freezing, as repeated freeze-thaw cycles can compromise stability.

• Humidity Control
  Brorphine should be kept in a dry environment to prevent clumping or degradation. Desiccants or silica packs can be used within storage containers.

• Protection from Light
  Exposure to UV or fluorescent light may degrade the compound. Store in amber glass containers or in a darkened cabinet.

• Air-Tight Containers
  Use double-sealed, chemical-resistant vials to prevent contamination from moisture, air, or other lab chemicals.

• Access Restriction
  Only trained staff should have access to the storage unit. Consider using locked cabinets or safes if regulations or lab policies require it.

• Labeling for Safety Compliance
  Include all necessary hazard warnings and handling instructions directly on the storage container to ensure consistent lab safety practices.

• Shelf-Life Monitoring
  While Brorphine remains stable for up to 24 months under proper storage conditions, record the opening date and conduct periodic inspections for signs of degradation.

Brorphine demonstrates moderate solubility in organic solvents, making it suitable for a range of laboratory applications including chromatography, spectroscopy, and receptor binding assays. It has poor solubility in water, which limits its use in aqueous environments.

• DMSO (Dimethyl Sulfoxide)
  Brorphine dissolves efficiently in DMSO, which is a preferred solvent for biological assays due to its compatibility with cell-based systems.

• Ethanol
  Ethanol is another common solvent, especially for extraction, thin-layer chromatography (TLC), or compound preparation for spectroscopic analysis.

• Methanol
  Methanol offers good miscibility and is often used in high-performance liquid chromatography (HPLC) protocols involving Brorphine.

• Acetonitrile
  Acetonitrile may be suitable for analytical procedures like LC-MS, though solubility may vary depending on concentration and temperature.

• Water Insolubility
  Brorphine has low to negligible solubility in water, which precludes its use in many physiological buffer solutions without the aid of co-solvents.

• Compatibility with Buffers
  It may precipitate in phosphate-buffered saline (PBS) or other aqueous buffers, so solvents should be chosen based on assay requirements.

• Use of Cosolvents
  In some experiments, Brorphine is dissolved in DMSO and diluted into an aqueous medium containing surfactants or cyclodextrins to maintain solubility.

At RC Plug, we provide Brorphine in a research-appropriate crystalline powder form. This format allows for precise measurement and reproducible use in various analytical and toxicological experiments.

• Crystalline Powder Appearance
  Brorphine is supplied as a white to off-white crystalline powder, which is fine-textured and free-flowing under dry conditions.

• High Purity Standards
  Our product is verified to contain ≥98% purity using HPLC testing to ensure that it meets research-grade quality benchmarks.

• Free of Additives or Fillers
  We do not include any cutting agents, excipients, or fillers. The powder is 100% pure Brorphine for accurate dosing and characterization.

• Pre-Weighed or Bulk Quantities
  Depending on order size, we offer pre-weighed vials for small-scale analysis or bulk packaging for institutional labs and large-scale study designs.

• Sealed and Protected Packaging
  The product is vacuum-sealed and placed in airtight, light-blocking containers to maintain integrity during storage and transport.

• Compatible with Lab Equipment
  The powder form allows for easy transfer using micro-spatulas, syringes (when dissolved), or analytical balances without compromising sample quality.

• Lot-Specific Documentation
  Every order includes a batch number and CoA (Certificate of Analysis) upon request, allowing traceability for regulatory or academic reporting.

Brorphine is not commonly included in routine toxicology panels, but specialized or updated laboratories may test for it using advanced instrumentation. As a novel synthetic opioid, its presence is often detected retrospectively or in targeted forensic assays.

• Not Detected by Standard Immunoassays
  Most rapid urine tests and workplace drug screens do not detect Brorphine, as their antibodies target traditional opioids or fentanyl derivatives.

• LC-MS/MS-Based Detection
  Liquid chromatography-tandem mass spectrometry (LC-MS/MS) can detect Brorphine with high sensitivity and specificity, especially when the testing panel is updated.

• Custom Toxicology Panels
  Forensic and toxicology labs increasingly include Brorphine in custom panels used to investigate overdose cases involving emerging synthetic opioids.

• Postmortem Testing
  Brorphine has been detected in postmortem toxicology reports, especially in the U.S., where it was linked to overdose clusters prior to DEA scheduling.

• Need for Reference Standards
  Detection requires authenticated reference materials, which are used to calibrate instruments and identify compound-specific retention times and fragmentation patterns.

• Retrospective Case Analysis
  Some toxicology labs re-analyze archived samples to determine if Brorphine contributed to previously unexplained opioid toxicities.

• Increasing Forensic Awareness
  As Brorphine gains attention in public health and forensic research, its inclusion in analytical panels is expected to increase.

While both Brorphine and fentanyl are potent synthetic opioids acting primarily on the μ-opioid receptor, their chemical structures, origins, and receptor interaction profiles differ significantly. Understanding these differences is essential for researchers evaluating structure–activity relationships, toxicity levels, and abuse potential among synthetic opioids.

• Different Core Structures
  Brorphine is a benzimidazole derivative, whereas fentanyl belongs to the anilide chemical class. This structural divergence influences how each compound interacts with opioid receptors and enzymes.

• Synthetic Origin
  Fentanyl was developed in the 1960s as a clinically approved analgesic. Brorphine, by contrast, was first identified in the 2010s and has no approved medical use, emerging instead as part of designer drug markets.

• Potency Comparison
  Fentanyl is estimated to be 50–100 times stronger than morphine, while Brorphine is 10–20 times stronger, making it less potent but still highly active in minute quantities.

• Duration and Onset
  Fentanyl has a rapid onset and short duration, often peaking in minutes. Brorphine exhibits a moderate onset with a slightly longer duration, typically lasting 3–6 hours in experimental models.

• Receptor Selectivity
  Brorphine is believed to be more selective for μ-opioid receptors without significant binding to δ or κ receptors, whereas fentanyl may show broader receptor interaction depending on analog variation.

• Detection in Toxicology
  Fentanyl is widely tested in clinical and forensic settings. Brorphine, however, often requires specialized mass spectrometry techniques and is not included in routine screening panels.

• Risk Profile in Research
  While both substances carry significant safety risks, Brorphine’s novelty and lack of clinical data make it less predictable, necessitating stricter handling protocols in the lab.

The research community views Brorphine as a concerning and powerful synthetic opioid with limited scientific literature but growing forensic interest. Its emergence in overdose cases and unique structural properties have led to increased scrutiny in both toxicology and pharmacology fields.

• Novelty as a Research Compound
  Brorphine is considered a next-generation opioid analog, valuable in receptor-binding studies, overdose modeling, and toxicological profiling.

• Concerns Over Illicit Use
  Researchers and public health officials have expressed alarm over Brorphine’s role in unregulated drug markets, especially prior to its formal scheduling by agencies like the DEA.

• Interest in Structure–Activity Research
  Its benzimidazole core has become a subject of interest in SAR studies, offering insights into how new opioid analogs might be designed and regulated.

• Limited Peer-Reviewed Studies
  Despite its growing prominence, Brorphine remains understudied in peer-reviewed scientific literature, leaving many unknowns about its long-term effects and mechanisms.

• Relevance in Overdose Surveillance
  Toxicologists and forensic chemists have included Brorphine in retrospective screening protocols to better understand its impact on the synthetic opioid epidemic.

• Collaboration with Regulatory Agencies
  Research institutions have begun working with agencies to provide analytical standards and toxicology reports on Brorphine, contributing to public health responses.

• Ethical Use Warnings
  Many publications emphasize the strict research-only usage of Brorphine, warning against its unregulated application in humans or animals.

Brorphine belongs to a broader group of synthetic opioids, many of which have similar receptor activity but differ in potency, duration, and structure. These compounds help researchers understand trends in opioid design and improve detection or regulation strategies.

• Isotonitazene
  A highly potent benzimidazole analog structurally related to Brorphine, often studied in parallel for its μ-opioid receptor binding and overdose potential.

• Etonitazene
  One of the earliest known benzimidazole opioids, used as a reference compound in potency studies due to its extreme receptor activity (more potent than morphine or fentanyl).

• Metonitazene
  Another emerging compound in the same structural class, useful for SAR comparison and toxicology cross-analysis.

• U-47700
  A structurally different opioid from the U-series, but often compared with Brorphine in receptor selectivity and fatality case studies.

• Fentanyl Analogs (e.g., Carfentanil)
  Though not benzimidazoles, fentanyl derivatives are frequently assessed alongside Brorphine to evaluate relative potency and forensic detectability.

• O-Desmethyltramadol
  A major active metabolite of tramadol, used in comparative potency and safety modeling due to its partial μ-opioid activity.

• Novel Psychoactive Substances (NPS) Databases
  Compounds structurally similar to Brorphine are regularly included in NPS surveillance programs, helping researchers stay updated on synthetic opioid emergence.

Disposing of Brorphine requires adherence to hazardous chemical disposal protocols. Improper disposal can result in environmental contamination, health risks, or regulatory violations. Labs must work with approved waste management services to handle Brorphine safely.

• Classify as Hazardous Waste
  Brorphine should be treated as Schedule I hazardous waste in regulated jurisdictions. It must never be discarded down drains or in general trash.

• Use Chemical Waste Disposal Vendors
  Partner with licensed hazardous waste disposal companies to manage unused Brorphine. Ensure documentation complies with local environmental laws.

• Label and Segregate
  Clearly label waste containers with “Brorphine — Opioid Research Chemical” and segregate from other lab waste streams to avoid cross-contamination.

• Avoid Incineration on Site
  Do not attempt to incinerate or chemically degrade Brorphine in-house unless your facility is licensed and equipped for high-temperature opioid waste disposal.

• Temporary Storage Guidelines
  Until disposal pickup, store unused Brorphine in sealed, leak-proof containers in a locked hazardous materials cabinet.

• Document Chain of Custody
  Maintain a complete waste disposal log, including amount, storage duration, disposal vendor, and personnel involved in disposal.

• Follow Institutional Policies
  Universities and research institutions often have strict SOPs for disposing of Schedule I substances. Always check and follow internal guidelines.

When stored under proper laboratory conditions, Brorphine remains chemically stable for extended periods. However, improper storage—such as exposure to moisture, light, or high temperatures—can cause degradation, impacting both safety and efficacy in experiments.

• Maintains Stability at 2–8°C
  Studies and manufacturer data suggest Brorphine remains stable for up to 24 months when stored in a refrigerated environment.

• Sensitive to Humidity and Light
  Prolonged exposure to moisture can cause clumping or breakdown of the powder, while UV exposure may lead to chemical degradation.

• Color or Texture Changes Indicate Degradation
  If Brorphine changes color (e.g., yellowing) or texture (e.g., sticky or clumped), it may no longer be viable for precise research.

• Impact on Analytical Results
  Degraded samples can yield inconsistent assay results, especially in quantitative studies involving LC-MS or GC-MS.

• Risk of Reduced Potency
  Over time, improperly stored Brorphine may experience loss of receptor-binding affinity, leading to skewed pharmacological data.

• Avoid Frequent Air Exposure
  Repeatedly opening containers introduces oxygen and moisture. Use small aliquots or single-use vials to minimize degradation risks.

• Re-testing for Critical Experiments
  For critical assays or publications, consider re-analyzing older Brorphine stock via HPLC or NMR to confirm chemical integrity before use.

Brorphine typically cannot be detected by standard field drug tests used by law enforcement or workplace screening programs. Its unique chemical structure sets it apart from commonly screened opioids, making it invisible to most immunoassay-based kits. Detection requires advanced laboratory testing and is generally limited to forensic or toxicological labs.

• Immunoassays Lack Specificity
  Most field drug tests rely on immunoassays, which use antibodies to detect specific substances. Brorphine’s novel structure means that standard opioid panels won’t react to it.

• False Negatives Are Common
  Individuals or samples containing Brorphine often test negative for opioids using field kits, leading to underreporting in forensic and clinical settings.

• Requires Instrumental Analysis
  Detection of Brorphine typically requires LC-MS/MS or GC-MS, which are laboratory techniques not available in field conditions.

• Custom Test Development
  Forensic labs can develop compound-specific assays, but these require access to reference standards and validation processes that are impractical for on-the-spot testing.

• Retrospective Identification
  In some cases, samples that initially test negative are later found to contain Brorphine when sent for in-depth toxicology analysis.

• Growing Inclusion in Forensic Panels
  As awareness of Brorphine increases, some advanced labs are adding it to their screening libraries, particularly in overdose investigations.

• No Cross-Reactivity with Fentanyl Tests
  Despite some similarities in effect, Brorphine does not cross-react with rapid fentanyl detection kits.